Compare DexCom, Inc. (DXCM) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Plby Group Inc — how do they compare? DexCom, Inc. trades at $76.86 (market cap $28.06B), while Plby Group Inc trades at $1.13 (market cap $128.89M). The key difference: DexCom, Inc. is far larger — about 217.7× Plby Group Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | PLBY | |
|---|---|---|
Market Cap | $28.06B | $128.89M |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $2.71 |
52-Week Low | $54.84 | $1.11 |
Enterprise Value | $27.03B | $276.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
PLBY trades at $1.10, down 5.98% today, with a bearish technical outlook despite oversold RSI signals. The company reported Q1 2026 revenue of $30.2M and a narrowed net loss of $4.0M, showing improved adjusted EBITDA. Recent developments include inclusion in Russell indexes and a share repurchase program. The stock's valuation shows a P/S of 0.96 and negative profitability metrics, with total liabilities exceeding assets.
The outlook remains challenged by persistent net losses and high debt, though cost controls and strategic focus show early progress. Analyst consensus is bullish with 75% buy ratings, but execution risks and brand licensing concerns pose significant headwinds for shareholder value recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
